Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting under SEBI LODR Regulations 30 and 33
Audit Opinion:
The statutory auditors, Deepak Jindal & Co., conducted a limited review and issued an unmodified review report. Nothing came to their attention to believe the financial results contain any material misstatement.
Key Financial Highlights [₹ in Lacs]:
Standalone Results:
Revenue from Operations: ₹1.45 (Sales) + ₹42.76 (Other operating income) = ₹44.21
Total Income: ₹629.47
Net Profit: (₹1,313.52) loss
EPS: (₹0.68) basic and diluted for continuing & discontinued operations
Consolidated Results:
Revenue from Operations: ₹1.45 (Sales) + ₹42.76 (Other operating income) = ₹44.21
Total Income: ₹336.20
Net Profit: (₹1,539.77) loss
EPS: (₹0.79) basic and diluted for continuing & discontinued operations
Financial Performance Analysis:
The company reported significant losses at both standalone and consolidated levels. The standalone net loss for the quarter was ₹1,313.52 lacs, while the consolidated net loss was ₹1,539.77 lacs. This performance represents a material deterioration from the profit of ₹8.80 lacs in the continuing operations for the same quarter last year (Q1 FY26).
Segment-wise Performance:
The company is exclusively in the pharmaceutical business segment, though it is transitioning to real estate.
Corporate Actions:
- Appointed Dr. Gunmala Suri (DIN: 11879344) as an Additional Director (Non-Executive Non-Independent) from August 15, 2026, till the forthcoming AGM, subject to shareholder approval.
- To convene the 31st Annual General Meeting (AGM) on Friday, September 18, 2026.
- Book closure for AGM from September 12, 2026, to September 18, 2026 (both days inclusive). Cut-off date for e-voting eligibility is September 11, 2026.
- Proposed re-appointment of Mr. Sanjiv Goyal (DIN: 00002841), who retires by rotation.
- Proposed appointment of Dr. Gunmala Suri as a regular director (Non-Executive Non-Independent) from August 15, 2026, subject to shareholder approval.
Other Significant Information:
Strategic Pivot and Asset Monetization:
- The company sold a substantial part of its business operations via a slump sale in the previous financial year, resulting in significant liquidity which was used to discharge all debts.
- The company has amended its object clause to undertake activities in the real estate sector and is evaluating various projects under this revised framework.
- It acquired Avensis Exports Private Limited (AEPL) as a wholly owned subsidiary to support this objective.
- The Board affirms the company's status as a going concern due to its solvent financial position and available funds.
Material Transactions and Discontinued Operations:
- The results of disposed businesses/assets (Capsule Business and others) are disclosed as discontinued operations under Ind AS 105.
- Capsule Business (EHGC): Sold to Capnest Health Care Private Limited for a consideration of ₹1,990.00 lakhs via a Business Transfer Agreement dated December 20, 2025. The transaction is pending completion.
- Other Assets: The company is monetizing non-core assets including the Jammu Unit (fixed assets, disposed of in the subsequent quarter) and vacant land near Garhshankar, Punjab (a portion sold in the current quarter, balance expected to be sold by FY27 end).
Investment Loss:
- The company recognized a loss of ₹2,513.29 lakhs (₹25.13 crore) on investments in mutual funds, ETFs, and equity instruments due to market volatility. This loss is classified under continuing operations and significantly impacted the quarterly results.